Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

China Health Group Limited
中國衛生集團有限公司

(Carrying on business in Hong Kong as CHG HS Limited)
(Incorporated in Bermuda with limited liability)
(Stock Code: 673)

(1) FURTHER EXTENSION OF LONG STOP DATE IN RELATION TO THE MAJOR TRANACTION REGARDING ACQUISITION OF 100% EQUITY INTEREST IN THE TARGET COMPANY INVOLVING THE ISSUE OF CONSIDERATION SHARES UNDER SPECIFIC MANDATE; AND (2) FURTHER DELAY IN DESPATCH OF CIRCULAR

Reference is made to (i) the announcement of China Health Group Limited (the "**Company**") dated 7 July 2024 in relation to the proposed acquisition of 100% equity interest in ProteinT (Tianjin) Diagnostic, Co., Ltd.*（譜天福信（天津）分子診斷技術有限公司）(the "**Acquisition**"); (ii) the announcements of the Company dated 21 August 2024 and 30 September 2024 in relation to the delay in despatch of the circular (the "**Circular**") in respect of the Acquisition; and (iii) the announcement of the Company dated 31 October 2024 in relation to the extension of long stop date in respect of the Acquisition and the further delay in despatch of the Circular (the "**Extension Announcement**") (collectively, the "**Announcements**"). Unless the context otherwise requires, capitalised terms used herein shall have the same meanings as those in the Announcements.

FURTHER EXTENSION OF LONG STOP DATE

As disclosed in the Extension Announcement, on 31 October 2024, the Purchaser, the Company, the Vendor, the Vendor Nominee and the Guarantor, as parties to the Agreement (the "**Parties**"), entered into a supplemental agreement (the "**First Supplemental Agreement**") to extend the Long Stop Date from 31 October 2024 to 28 February 2025 (or such later date as agreed by the parties to the Agreement in writing).

As additional time is required for the preparation of the Circular required under the Listing Rules, which is, among others, one of the Conditions Precedent, on 28 February 2025, the Parties entered into a second supplemental agreement to further extend the Long Stop Date from 28 February 2025 to 30 June 2025 (or such later date as agreed by the parties to the Agreement in writing). Save for the extension of the Long Stop Date, all other terms and conditions of the Agreement (as amended and supplemented by the First Supplemental Agreement) remain unchanged and in full force and effect in all respects.

FURTHER DELAY IN DESPATCH OF CIRCULAR

As disclosed in the Extension Announcement, the Circular was expected to be despatched to the Shareholders on or before 28 February 2025. As additional time is required for the Company to prepare and finalise certain information to be included in the Circular, it is expected that the despatch date of the Circular will be postponed to a date on or before 30 June 2025.

By order of the Board
China Health Group Limited
Chung Ho
Chief Executive Officer and Executive Director

Hong Kong, 28 February 2025

As at the date of this announcement, the Board comprises three executive Directors, namely, Mr. Zhang Fan (chairman), Mr. Chung Ho and Mr. Xing Yong; two non-executive Directors, namely, Mr. Huang Lianhai and Mr. Wang Jingming; and four independent non-executive Directors, namely, Mr. Jiang Xuejun, Mr. Du Yanhua, Mr. Lai Liangquan and Ms. Yang Huimin.

* *For identification purposes only*